ArticleBritish journal of cancer2010
The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model.
Article in British journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 42 citations in OpenAlex.
- Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma.European journal of cancer (Oxford, England : 1990) · 2020Trial
- Antithrombotic therapy for a case report of acute myocardial infarction after laparoscopic radical cystectomy.Frontiers in pharmacology · 2024Article
- Heparanase and the hallmarks of cancer.Journal of translational medicine · 2020Review
- Antitumor effects of nadroparin combined with radiotherapy in Lewis lung cancer models.OncoTargets and therapy · 2018Article
- Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications.Medical oncology (Northwood, London, England) · 2017Review
- Smart Carriers and Nanohealers: A Nanomedical Insight on Natural Polymers.Materials (Basel, Switzerland) · 2017Review
- Intravital Microscopy Imaging Approaches for Image-Guided Drug Delivery Systems.Current drug targets · 2015Review
- Effect of bone marrow mesenchymal stem cells on hepatocellular carcinoma in microcirculation.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- The mechanisms of nadroparin-mediated inhibition of proliferation of two human lung cancer cell lines.Cell proliferation · 2012Article
- Intravital microscopy in the mouse dorsal chamber model for the study of solid tumors.American journal of cancer research · 2011Article
- Intravital microscopy as a tool to study drug delivery in preclinical studies.Advanced drug delivery reviewsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, low-molecular-weight heparins (LMWHs) were found to confer a survival advantage in cancer patients. The mechanism underlying this observation is unclear, but may involve inhibition of tumour angiogenesis. We aimed to examine the effects of nadroparin on tumour angiogenesis using a dorsal skinfold window chamber model in the Syrian hamster.
methodsAMel-3 and HAP-T1 tumours were grown in donor animals and fragments implanted in the window chambers. Animals (N=46) were treated with 200 IU of nadroparin or saline for 10 days. Repeated intravital fluorescence microscopy was performed to calculate functional microcirculatory parameters: number (N) and length (L) of microvessels, vascular area fraction (AF), and red blood cell velocity (V). Microvessel density (MVD), fractal dimension, and pericyte coverage were assessed histologically.
resultsActive angiogenesis was observed in control animals, resulting in a significant increase in N, L, and AF. In nadroparin-treated animals, however, N and L did not increase whereas AF decreased significantly. Both groups showed an initial increase in V, but nadroparin treatment resulted in an earlier decrease in red blood cell velocity over time. Compared with control animals, nadroparin-treated animals showed a significantly lower MVD and fractal dimension but significantly higher pericyte coverage index (PCI).
conclusionsTaken together, these results suggest that the LMWH nadroparin inhibits tumour angiogenesis and results in microvessel normalisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.